Oppenheimer lowered the firm’s price target on Acrivon Therapeutics (ACRV) to $10 from $18 and keeps an Outperform rating on the shares following Q4 results and management’s guidance on ACR-368. The firm notes the focus is now on endometrial cancer, while ovarian and bladder cancer are being de-prioritized. In the ACR-2316 program, management announced that early signs of clinical activity have been observed – a clinical data update is slated for the second half of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c)
- Acrivon Therapeutics Reports 2024 Financial Results and Progress
- Promising Phase 2 Results for ACR-368 in Endometrial Cancer Justify Buy Rating
- Acrivon Therapeutics price target lowered to $19 from $22 at H.C. Wainwright
- Acrivon Therapeutics, Inc. (ACRV) Q4 Earnings Cheat Sheet